A Study for Exploring the Efficacy of Naoxintong Capsules in the Treatment of Coronary Atherosclerotic Plaque on the Basis of Optimal Medical Therapy (Aspirin,Statins,Clopidogrel, Etc.): Stage One

Inclusion Criteria: 1. Signing informed consent; 2. Male or female aged 18 to 75 years old; 3. AMI patients with selective PCI indication primary PCI patients are exclusive; 4. No history of CABG or PCI; Image inclusion criteria: 1. CCTA at least one in-segment ≥20% and ≤70% diameter stenosis non-culprit vessel in the proximal-middle segments of RCA, LCX, LAD (the proximal and distal plaque within 5mm, same as below); 2. Radiography diameter of target vessel, 2.5-4.0mm; 3. Studied vessel can be evaluated with OCT and IVUS; OCT: the visual target study lesion is lipid-rich plaque with lipid arc≥100 degree and fiber cap thickness≤120µm. Exclusion Criteria: 1. Life expectancy is less than 1 year; 2. Cannot implant drug stent; 3. Received ≥4weeks systematic treatment of statin and other lipid-lowering drug in the 3 months before admission; 4. Received ≥4 weeks systematic treatment of any traditional Chinese medicine; 5. Known to have adverse reaction to ingredients of NXT capsule; 6. Patients with severe heart disease that CABG or selective PCI, heart transplantationSAVR/TAVR are required during the study(12 months); 7. LVEF\<40%; 8. Drug uncontrollable recurrent and highly symptomatic arrhythmia such as ventricular tachycaidia, atrial fibrillation with rapid ventricular rate and paroxysmal supraventricular tachycardia in the 3 months before ACS admission; 9. Known any stroke; 10. Other operations arranged during the study period (12 months); 11. Uncontrollable hypertension, defined as resting systolic BP≥180mmHg; 12. Clinical confirmed as statin intolerance; 13. Type I diabetes or type 2 diabetes that is not well controlled; 14. Moderate and severe renal dysfunction (defined as eGFR\<30ml/min/1.73m2); 15. Clinical confirmed liver disease or liver dysfunction (AST or ALT \>3\*ULN); 16. Clinical confirmed infection and other hematological, metabolic gastrointestinal or endocrine dysfunction that researchers believe not suitable for enrollment; 17. Known factors that may not be compliant, such as alcoholism, drug addiction, mental illness, etc.; 18. Participated in other clinical research projects, or within 30 days of the last participating clinical project; 19. Pregnant,breast feeding women or those plan to conceive during the study; 20. History of malignant tumor. Lesion related: 1. Target segment severe calcification; 2. Failed PCI in culprit vessel; 3. Failed OCT screening (lipid arc/ fiber cap thickness does not match filter criteria); 4. Complications during the evaluation of OCT and IVUS/VH-IVUSOCT and IVUS/VH-IVUS evaluation failed due to instruments.